Evidence map›Paper›PMID 38006197›Full record

ArticleThe oncologist2024

Treatment of Hypercalcemic Hyperparathyroidism After Kidney Transplantation Is Associated With Improved Allograft Survival.

Rongzhi Wang, Rhiannon D Reed, Griffin Price, Peter Abraham, Marshall Lewis, Jessica Liu McMullin, Paul MacLennan, Cozette Killian, Jayme E Locke, Song Ong and 5 more

Abstract read

PubMed Full text at PMC Publisher

In one paragraph

Article in The oncologist, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it

0cells of the map it votes in

6citing papers in PubMed

–field-weighted citation impact

1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed.

The Prevalence and Risk Factors for Persistent Hyperparathyroidism in Post-Kidney Transplant Patients: A Single-Center Retrospective Study.Journal of the ASEAN Federation of Endocrine Societies · 2026
Article
Parathyroidectomy timing for persistent hyperparathyroidism in kidney transplant candidates and recipients: from secondary to tertiary disease: a literature review.Gland surgery · 2026
Review
Post-transplantation management of hyperparathyroidism and its association with kidney graft survival and fibrosis.Clinical and experimental nephrology · 2025
Article
Effect of Parathyroidectomy Timing on the Successful Resolution of Tertiary Hyperparathyroidism in Kidney Transplant Recipients: A Systematic Review and Meta-Analysis.Journal of clinical medicine · 2025
Review
Intraoperative parathyroid hormone monitoring to guide surgery in renal hyperparathyroidism (PEREGRINE): a protocol for a randomised multiarm surgical pilot trial.BMJ open · 2025
Article
Predictors of Hungry Bone Syndrome and Reintervention After Subtotal Versus Total Parathyroidectomy for Secondary Hyperparathyroidism in Dialysis Patients: A Single-Center Cohort.Journal of clinical medicine · 2025
Article

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors.

Rongzhi WangDepartment of Surgery, University of Alabama at Birmingham Heersink School of Medicine, Birmingham, AL, USA.ORCID 0000-0002-3790-7840

Rhiannon D ReedDepartment of Surgery, University of Alabama at Birmingham Heersink School of Medicine, Birmingham, AL, USA.

Griffin PriceSchool of Medicine, University of Alabama at Birmingham Heersink School of Medicine, Birmingham, AL, USA.

Peter AbrahamDepartment of Surgery, University of Alabama at Birmingham Heersink School of Medicine, Birmingham, AL, USA.

Marshall LewisSchool of Medicine, University of Alabama at Birmingham Heersink School of Medicine, Birmingham, AL, USA.

Jessica Liu McMullinDepartment of Surgery, University of Alabama at Birmingham Heersink School of Medicine, Birmingham, AL, USA.

Paul MacLennanDepartment of Surgery, University of Alabama at Birmingham Heersink School of Medicine, Birmingham, AL, USA.

Cozette KillianDepartment of Surgery, University of Alabama at Birmingham Heersink School of Medicine, Birmingham, AL, USA.

Jayme E LockeDepartment of Surgery, University of Alabama at Birmingham Heersink School of Medicine, Birmingham, AL, USA.

Song OngDepartment of Medicine, University of Alabama at Birmingham Heersink School of Medicine, Birmingham, AL, USA.

Vineeta KumarDepartment of Medicine, University of Alabama at Birmingham Heersink School of Medicine, Birmingham, AL, USA.

Andrea GillisDepartment of Surgery, University of Alabama at Birmingham Heersink School of Medicine, Birmingham, AL, USA.ORCID 0000-0002-4481-5549

Brenessa LindemanDepartment of Surgery, University of Alabama at Birmingham Heersink School of Medicine, Birmingham, AL, USA.

Herbert ChenDepartment of Surgery, University of Alabama at Birmingham Heersink School of Medicine, Birmingham, AL, USA.

Jessica FazendinDepartment of Surgery, University of Alabama at Birmingham Heersink School of Medicine, Birmingham, AL, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundHyperparathyroidism (HPT) and malignancy are the most common causes of hypercalcemia. Among kidney transplant (KT) recipients, hypercalcemia is mostly caused by tertiary HPT. Persistent tertiary HPT after KT is associated with allograft failure. Previous studies on managing tHPT were subjected to survivor treatment selection bias; as such, the impact of tertiary HPT treatment on allograft function remained unclear. We aim to assess the association between hypercalcemic tertiary HPT treatment and kidney allograft survival. MATERIALS AND

methodsWe identified 280 KT recipients (2015-2019) with elevated post-KT adjusted serum calcium and parathyroid hormone (PTH). KT recipients were characterized by treatment: cinacalcet, parathyroidectomy, or no treatment. Time-varying Cox regression with delayed entry at the time of first elevated post-KT calcium was conducted, and death-censored and all-cause allograft failure were compared by treatment groups.

resultsOf the 280 recipients with tHPT, 49 underwent PTx, and 98 received cinacalcet. The median time from KT to first elevated calcium was 1 month (IQR: 0-4). The median time from first elevated calcium to receiving cinacalcet and parathyroidectomy was 0(IQR: 0-3) and 13(IQR: 8-23) months, respectively. KT recipients with no treatment had shorter dialysis vintage (P = .017) and lower PTH at KT (P = .002), later onset of hypercalcemia post-KT (P < .001). Treatment with PTx (adjusted hazard ratio (aHR) = 0.18, 95%CI 0.04-0.76, P = .02) or cinacalcet (aHR = 0.14, 95%CI 0.004-0.47, P = .002) was associated with lower risk of death-censored allograft failure. Moreover, receipt of PTx (aHR = 0.28, 95%CI 0.12-0.66, P < .001) or cinacalcet (aHR = 0.38, 95%CI 0.22-0.66, P < .001) was associated with lower risk of all-cause allograft failure.

conclusionsThis study demonstrates that treatment of hypercalcemic tertiary HPT post-KT is associated with improved allograft survival. Although these findings are not specific to hypercalcemia of malignancy, they do demonstrate the negative impact of hypercalcemic tertiary HPT on kidney function. Hypercalcemic HPT should be screened and aggressively treated post-KT.

Indexed as

HypercalcemiaHyperparathyroidismHyperparathyroidism, SecondaryKidney TransplantationNeoplasmsAllograftsCalciumCinacalcetHumansParathyroidectomyParathyroid HormoneRetrospective StudiesCalciumCinacalcetParathyroid Hormoneallograft functionhypercalcemiahyperparathyroidismkidney transplant

Identifiers

PMID38006197

DOI10.1093/oncolo/oyad314

PMCPMC10994253

What Socratic holds

Textmetadata

LicenceCC BY

Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.